Dyne Therapeutics has launched in the US with $50m of series A funding to develop targeted therapies for the treatment of patients suffering from serious muscle diseases.

The biotechnology firm was founded by Atlas Venture, which led the series A financing round. Forbion and MPM Capital also joined the round.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

To develop targeted therapies, Dyne Therapeutics will leverage its FORCE platform, which delivers nucleic acids and other molecules specifically to skeletal, cardiac and smooth muscle.

Findings from preclinical studies suggest that the new approach could deliver oligonucleotides that destroy disease-causing RNA and potentially restore muscle health.

The company designed its lead programmes to ‘knock down’ gene expression in order to treat rare, monogenic neuromuscular disorders. It is focused on offering therapies for cardiac and smooth muscle diseases.

“Dyne’s breakthrough approach brings the power of modern oligo therapeutics and other payloads to patients with serious muscle diseases.”

Initially, Dyne Therapeutics will work to address a rare inherited condition called myotonic dystrophy type 1 (DM1).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

DM1, which impacts approximately 40,000 people in the US, causes muscle weakness and additional complications. It currently lacks disease-modifying treatments.

Dyne Therapeutics president and CEO Romesh Subramanian said: “We are launching with a singular goal: to change the lives of patients with DM1 and other serious muscle diseases. Our innovative approach makes this possible, and our commitment to patients and their families makes it necessary.”

Previously, Subramanian co-founded RaNA Therapeutics, now Translate Bio, and was responsible for new modality discovery research at Alexion Pharmaceuticals.

Atlas Venture partner Jason Rhodes and Dyne Therapeutics board of directors executive chairman said: “Dyne’s breakthrough approach brings the power of modern oligo therapeutics and other payloads to patients with serious muscle diseases.

“The combination of tissue-specific delivery, high potency and tolerability enable a broad product pipeline. We are pleased to be working with Dyne’s exceptional team and SAB and to have Forbion and MPM Capital as partners as we build the company together.”